Melissa B. Davis, PhD

Lab Groups & Research Areas

Davis Lab Cancer

Dr. Davis received her Ph.D. in Molecular Genetics at the University of Georgia (Athens, GA, USA) where she completed groundbreaking work on developmental functions of steroid signaling in model organisms. She completed postdoctoral training in Functional Genomics and Systems Biology at Yale School of Medicine (Human Genetics) and the University of Chicago (Human Genetics and Institute for Genomics and Systems Biology). Here work involved key elements of the ModENCODE project, showing the genome-wide and tissue-specific dynamics of hormone receptor binding, establishing the dynamics of these functions on a cellular level. Her postdoctoral training in Cancer Health Disparities at University of Chicago at the Interdisciplinary Center for Health Disparities, led the current trajectory of her work to uncover the biological determinants of cancer health disparities and how they intersect with marginalization of minoritized population.

Melissa B. Davis, PhD is the newly appointed Director of the Institute of Translational Genomic Medicine at Morehouse School of Medicine, and Distinguished Investigator with the Georgia Research Alliance. She also serves as Scientific Director of the International Center for the Study of Breast Cancer Subtypes (ICSBCS), (Interim) Director of Health Equity for the Englander Institute of Precision Medicine and Associate Professor of Cell and Developmental Biology in the Department of Surgery and at Weill Cornell Medicine in New York, NY. She is also a Cancer Ethnicity Scholar, co leading the PolyEthnic-1000 project at New York Genome Center.

Dr. Davis’s has published groundbreaking findings that established a new lens to study associations of biological factors in cancer outcomes as related to genetic ancestry. Specifically, she has discovered links between African ancestry and tumor burdens that have a disproportionate burden in people across the African diaspora. Dr. Davis is a pioneer in the field of “disparities genomics,” with specific focus in breast cancer expanding into prostate and gynecological cancers in recent years. Her current findings involve utilizing quantified ancestry to unravel genetic vs environmental influences in tumor biology among race/ethnic groups, including epigenetic cell signaling and immunological responses in the tumor microenvironment and systemic immune regulation. These novel opportunities to develop precision medicine applications in minority populations, are part of a concerted effort to increase knowledge of genomic profiles of underrepresented minoritized and under-represented cancer patients. Her work is a prime example of how inclusion of diverse ethnic groups can empower research designs for discovery of novel or unique tumor biology.